Atara Biotherapeutics, an early-stage biotech targeting muscle loss in patients with end-stage renal disease, announced terms for its IPO on Thursday. The Brisbane, CA-based company plans to raise $75 million by offering 5.0 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Atara would command a fully diluted market value of $305 million.
Atara Biotherapeutics, which was founded in 2012, plans to list on the NASDAQ under the symbol ATRA. Atara initially filed confidentially on April 10, 2014. Goldman Sachs and Citi are the joint bookrunners on the deal. It is expected to price during the week of July 21, 2014.
